IRVING, Texas, Apr 29, 2004 /PRNewswire-FirstCall via COMTEX/ -- Carrington Laboratories, Inc., (Nasdaq: CARN) announced it has created a semi-annual scholarship fund with the Wound, Ostomy and Continence Nurses Society (WOCN) in honor of the late Sheri H. Smith, RN, PhD, CETN, CWS, former vice president of the Medical Services Division of the Company and award-winning, long-time member of the WOCN. The Dr. Sheri Smith Memorial Award in the amount of $2,500 will be awarded twice annually to an applicant selected by a six-member panel of WOCN members. Award recipients must be a nurse seeking education in wound, ostomy and continence nursing care and must be accepted or enrolled in a WOC Education Program.
Dr. Smith was an active member of the WOCN from 1992 until her death in August 2003 which resulted from complications of a bone marrow transplant. She was the recipient of the Southeast Region WOCN Researcher Award in 1996. She joined Carrington in 1996 to support Carrington's advanced wound care products and educate clinicians in their proper techniques and usage.
Dr. Carlton Turner, president and CEO of Carrington, stated, 'Sheri was a gifted clinician, an inspiring educator and truly an extraordinary woman who devoted her entire career to helping others. We feel that the most appropriate way to honor her memory is to continue in some way to assist others in achieving their nursing career goals.'
Carrington Laboratories, Inc., is an ISO 9001-certified, research-based biopharmaceutical company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care; manufacture and market the nutraceutical raw material Manapol(R); and market consumer products under the AloeCeuticals(R) brand. Carrington's technology is protected by more than 119 patents in 26 countries. Select products are honored with the internationally coveted CE mark, recognized by more than 20 countries around the world.
Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in production; changes in the regulatory process; changes in trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities &Exchange Commission, including the Form 10K filed March 19, 2004.